The vast reach of USAID’s NTD Program and the NTD treatments delivered have been made possible due to generous commitments from the pharmaceutical sector. Six of the drugs needed to eliminate and control NTDs are donated by the pharmaceutical companies Eisai, GlaxoSmithKline, Merck & Co., Merck KGaA, Johnson & Johnson and Pfizer. The USAID NTD Program works with countries to forecast and efficiently distribute these donated drugs to target audiences.
Since USAID’s NTD Program began distributing donated drugs in 2007, the drug donation programs have expanded significantly. The NTD drugs donated to the USAID-supported countries have been valued at over $19 billion, representing the largest public-private partnership in the Agency, with a leverage of $26 in donated drugs for every tax dollar spent by USAID.